London, ON -- (SBWIRE) -- 01/27/2016 -- Sernova Corp., a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize and validate Sernova's licensed technology for creating stem cell derived therapeutic cells that produce insulin and are glucose responsive.
Read the full press release at http://www.sbwire.com/press-releases/sernova-announces-agreement-with-ccrm-to-produce-specialized-cells-for-the-treatment-of-diabetes-660239.htm
